Effective 1 October 2024, the international legal practice Osborne Clarke has appointed Dr Andrea Schmoll as the head of the Life Sciences and Healthcare (LSH) sector group. With this move, the firm is further advancing the expansion of the interdisciplinary group, which supports companies in the biopharma, healthcare, and medtech sectors, particularly in IP law, regulatory, and transactional advice.
“Over the past year, the Life Sciences and Healthcare sector at Osborne Clarke has developed very positively in Germany as well as in Europe,” said Carsten Schneider, Managing Partner of Osborne Clarke Germany. “This positive trend will continue – from 1 October under the distinguished LSH and IP expert Dr Andrea Schmoll. This marks another step in our journey to becoming a leading advisor for Life Sciences and Healthcare clients – particularly in handling M&A, licensing, or R&D transactions.”
With a revenue of around EUR 8.2 million (more than 10% of Osborne Clarke's total revenue in Germany) in 2023, the sector group is a significant pillar of the firm. Around 40 lawyers from the fields of IP, corporate law and M&A, VC, regulatory, antitrust law, employment law, litigation, real estate, distribution law, and tax law are part of the Life Sciences and Healthcare sector in Germany. The newest member of the sector is Dr Florian Reiling, who joined Osborne Clarke as a partner from Clifford Chance in April and, together with Andrea Schmoll, manages the licensing transactions area. A particular specialty of the sector is advisory services in the transaction area – whether for cross-border M&A transactions (e.g. InstaDeep by BioNTech for EUR 410 million and Biotest AG by Grifols for EUR 1.1bn), joint ventures, or pharma cooperation and licensing agreements (e.g. BioNTech and DualityBio). Additionally, the team has many years of experience in medical device law, advising on regulatory issues, and supporting Life Sciences clients in digital transformation projects on topics such as AI, cloud migration, and data anonymisation concepts.
“Through our high degree of specialisation in IP law and regulatory advice, combined with our cross-practice expertise in transactions, we are well-positioned to comprehensively advise our clients in the Life Sciences and Healthcare sector on their current challenges,” said Schmoll. “I am particularly looking forward to further expanding our proven interdisciplinary approach. It is important to me to also involve our young colleagues early on to foster enthusiasm and awareness for life science-related legal issues.”
Schmoll also intends to maintain the strong international networking of the sector group. Not only in handling international transactions but also in joint marketing formats such as the successful Osborne Clarke Life Sciences Academy event series, which will continue with full force.
Corporate communications and press contacts
Connect with one of our experts
